Clarivate Names Highly Cited Researcher 2022 Designations
Nearly 7,000 researchers from across the globe received designations.
Clarivate Plc revealed its 2022 list of Highly Cited Researchers–individuals at universities, research institutes, and commercial organizations who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research. The methodology draws on data from the Web of Science™ citation index, together with analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.
ISI analysts have awarded Highly Cited Researcher 2022 designations to 6,938 researchers from across the globe who demonstrated significant influence in their chosen field or fields over the last decade. The list spans 69 countries or regions and is spread across a diverse range of research fields in the sciences and social sciences.
Read more about this story here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
